Nomogram for predicting overall survival in children with neuroblastoma based on SEER database

Abstract

This study was performed to establish and validate a nomogram for predicting the overall survival in children with neuroblastoma. Methods: The latest clinical data of neuroblastoma in Surveillance, Epidemiology, and End Results (SEER) database was extracted from 2000 to 2016. The cases included were randomly divided into training and validation cohorts. The survival curves were drawn with a Kaplan-Meier estimator to investigate the influences of certain single factors on overall survival. Also, least absolute shrinkage and selection operator regression was applied to further select the prognostic variables for neuroblastoma. Additionally, receiver operating characteristic (ROC) curves and calibration curves were used to evaluate the accuracy of the nomogram. Results: In total, 1,262 patients were collected and 8 independent prognostic factors were achieved, including patients' age, sex, race, tumor grade, radiotherapy, chemotherapy, tumor site, and tumor size. Then we constructed a nomogram by using the data of the training cohort with 886 cases. Subsequently, the nomogram was validated internally and externally with 886 and 376 cases, respectively. The internal validation revealed that the area under the curves (AUC) of ROC curves of 1-, 3-, and 5-year overall survival were 0.69, 0.78, and 0.81, respectively. Accordingly, the external validation also showed that the AUC of 1-, 3-, and 5-year overall survival were all ≥0.69. Both methods of validation demonstrated that the predictive calibration curves were consistent with standard curves. Conclusion: The nomogram possess the potential to be a new tool in predicting the survival rate of neuroblastoma patients.

Clinical Characteristics and Survival Outcomes in Neuroblastoma With Bone Metastasis Based on SEER Database Analysis

“…Although some studies have suggested that the tumor site was related to the prognosis of NB (16, 17), we did not observe an association between tumor site and survival time in this analysis. Tumor size was identified as an independent predictor of OS and CSS, corroborating evidence reported by recent studies (17,18). However, Zhou et al (19) found that tumor size did not exert a significant prognostic effect on the rate of event-free survival.…”

Prognostic impact of tumor size on patients with neuroblastoma in a SEER‐based study

“…Recently, a few studies have evaluated the significance of tumor size in predicting the prognosis of neuroblastoma patients. Liang et al divided patients into four subgroups based on tumor size (<5, 5.1–10, 10.1–15, and >15 cm), and found that patients with larger tumors often predict poor prognosis 21 . Moreover, He et al found that tumor size >10 cm was related to the poor overall survival in neuroblastoma patients with bone metastasis 22 .…”

Perfusion-Based Bioreactor Culture and Isothermal Microcalorimetry for Preclinical Drug Testing with the Carbonic Anhydrase Inhibitor SLC-0111 in Patient-Derived Neuroblastoma

“…Neuroblastoma arises from the sympathetic nervous system and is the most common solid tumor diagnosed in the first year of life [ 1 ]. With an incidence of 1:7000 to 1:8000, neuroblastoma is the most common extracranial solid malignancy in children [ 2 , 3 ]. Neuroblastoma is a heterogenous malignancy with a wide spectrum of cellular subtypes ranging from epithelial-like tissues to neuronal tissues with a wide variety of clinical manifestations.…”

“…Neuroblastoma is a heterogenous malignancy with a wide spectrum of cellular subtypes ranging from epithelial-like tissues to neuronal tissues with a wide variety of clinical manifestations. Although modern treatment strategies have led to increased survival rates, neuroblastoma still contributes to 15% of child deaths from cancer, and high-risk patients still face poor outcomes [ 2 , 3 ]. Characteristically, clinical behaviors and clinical outcomes are highly heterogeneous.…”